85951-60-6

Basic information

• Product Name: (S)-2-AMINO-7-HYDROXYTETRALIN
• Synonyms: (S)-2-AMINO-7-HYDROXYTETRALIN;(7S)-7-Amino-5,6,7,8-tetrahydro-2-naphthalenol;-2-AMino-7-hydroxyl-1,2,3,4;(S)-7-Amino-5,6,7,8-tetrahydro-naphthalen-2-ol;(S)-2-Amino-7-hydroxy-1,2,3,4-tetrahydronaphthalene;(S)-7-Amino-5,6,7,8-tetrahydro-2-naphthol;2-Naphthalenol, 7-amino-5,6,7,8-tetrahydro-, (7S)-;(3S)-3-Aminotetralin-6-ol
• CAS NO: 85951-60-6
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• Product Categories: Chiral Compounds
• Mol File: 85951-60-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: 144-148°C
• Boiling Point: 325.121 °C at 760 mmHg
• Flash Point: 150.428 °C
• Appearance: White to gray/Crystalline Powder
• Density: 1.147
• Storage Temp.: 2-8°C
• PKA: 10.21±0.20(Predicted)
• CAS DataBase Reference: (S)-2-AMINO-7-HYDROXYTETRALIN(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMINO-7-HYDROXYTETRALIN(85951-60-6)
• EPA Substance Registry System: (S)-2-AMINO-7-HYDROXYTETRALIN(85951-60-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• RIDADR: UN 3335
• WGK Germany: 3
• Hazardous Substances Data: 85951-60-6(Hazardous Substances Data)

Usage

General Description

(S)-2-Amino-7-hydroxytetralin, also known as 7-OH-DPAT, is a chemical compound that belongs to the class of tetralin derivatives. It acts as a selective agonist for the dopamine D3 receptor, and also exhibits some affinity for the dopamine D2 receptor. (S)-2-Amino-7-hydroxytetralin has been studied for its potential therapeutic effects in the treatment of various neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, and drug addiction. Its ability to selectively target dopamine receptors makes it a valuable tool for research in neuropharmacology and for the development of new medications. Additionally, its unique structure and pharmacological properties make it an interesting target for the synthesis of novel compounds with potential therapeutic applications.

Upstream product

• 231623-76-0 N-[(2S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide 
• 231623-74-8 N-(7-methoxy-3,4-dihydro-naphthalen-2-yl)-benzamide 
• 4133-34-0 7-methoxyl-2-tetralone 
• 132990-84-2 (2S)-N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 
• 603122-70-9 (7S)-7-(benzylamino)-5,6,7,8-tetrahydronaphthalen-2-ol 
• 4003-89-8 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 121216-42-0 (2S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 

Downstream Products

• 603122-37-8 (7S)-7-{[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenol 
• 121216-31-7 N-<(2S)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(2R)-2-(3-chlorphenyl)-2-hydroxyethanamine 
• 194785-39-2 benzyl [(2S)-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]carbamate 
• 121524-14-9 ((S)-7-{tert-Butoxycarbonyl-[(R)-2-(3-chloro-phenyl)-2-hydroxy-ethyl]-amino}-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-acetic acid ethyl ester 
• 121489-30-3 [(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethyl]-((S)-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid tert-butyl ester 
• 121489-29-0 tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][(2S)-7-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl]carbamate 
• 742664-85-3 N-<(2S)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(2S)-2-(3-chlorphenyl)-2-hydroxyethanamine 
• 121251-84-1 (-)-N-<(2S)-7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl>-(R)-3-chloromandelamide 
• 603121-99-9 3-[((7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]benzoic acid hydrochloride 
• 603121-98-8 3-[((7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-tert-butyloxycarbonylamino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]benzoic acid methyl ester 
• 603122-43-6 C₂₅H₂₅ClN₂O₃ 
• 603123-88-2 4-((7S)-7-{[(2R)-2-(4-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)-3-fluorobenzoic acid hydrochloride 
• 603124-11-4 C₃₀H₃₁ClFNO₅ 
• 603123-04-2 C₃₁H₃₃ClFNO₅ 

Relevant articles and documents

Discovery of a novel series of benzoic acid derivatives as potent and selective human β3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety

We designed a series of benzoic acid derivatives containing the biphenyl ether or biphenyl template on the RHS and a phenylethanolaminotetraline (PEAT) skeleton, which was prepared by highly stereoselective synthesis, to generate two structurally different lead compounds (10c, 10m) with a good balance of potency, selectivity, and pharmacokinetic profile. Further optimization of the two lead compounds to improve potency led to several potential candidates (i.e., 11f, 11l, 11o, 12b). In particular, biphenyl analogue 12b exhibited an excellent balance of high potency (EC50 = 0.38 nM) for β3, high selectivity over β1 and β2, and good pharmacokinetic properties in rats, dogs, and monkeys.